Loading...
Market
What will be the market share of Incyte's Niktimvo in the chronic GVHD treatment market by the end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Publicly available market research reports and financial statements from Incyte
Story
FDA Approves Incyte's Niktimvo for Chronic GVHD
Aug 14, 2024, 10:09 PM
The U.S. Food and Drug Administration (FDA) has approved Incyte Corporation's drug, Niktimvo™ (axatilimab-csfr), for the treatment of chronic graft-versus-host disease (GVHD). This condition is a potentially fatal complication that can occur after a stem cell transplant. The approval marks a significant advancement in the treatment options available for patients suffering from chronic GVHD. The drug, developed in collaboration with Syndax Pharmaceuticals, offers a new therapeutic option for managing this serious condition.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Over 30% • 25%
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%